graph Evidence gap map comparisons
lapatinib based treatment
lapatinib plus trastuzumab
la/mBC - HER2 positive - 2nd Line (L2) 13   
Comparator:  vs lapatinib; 
Risk of bias:  low;   some concerns;   high;  NA;